BTAF1: A Potential Drug Target and Biomarker for B-TFIID-Driven Tissue Degradation

Target Name: BTAF1

NCBI ID: G9044

BTAF1

BTAF1: A Potential Drug Target and Biomarker for B-TFIID-Driven Tissue Degradation

Introduction

The B-TFIID (Bioelectron Microscope-Confocal Imaging) system is a powerful tool for the study of tissue imaging and mechanical forces. It allows researchers to visualize the organization and dynamics of molecular machines in live cells with high resolution and sensitivity. One of the The key components of this system is the B-TFIID TATA-box binding protein associated factor 1 (BTAF1), which plays a critical role in the regulation of B-TFIID-mediated tissue degradation.

In this article, we will explore the structure and function of BTAF1, its potential as a drug target, and its role as a biomarker for the study of tissue degradation.

Structure and Function

BTAF1 is a 21-kDa protein that belongs to the superfamily of TATA-box binding proteins. It is expressed in a variety of tissues and cells, including muscle, heart, brain, and liver. BTAF1 functions as a negative regulator of B-TFIID -mediated tissue degradation, which is critical for maintaining the integrity of tissues and organs during various cellular and mechanical forces.

BTAF1 is composed of a unique nucleotide-binding domain, a TATA-box domain, and a C-terminal region that contains a series of conserved secondary structure elements. The nucleotide-binding domain is the site of BTAF1's binding to the B- TFIID protein. This domain is composed of a nucleotide-binding pocket, which is accessible to the nucleotide-binding proteins that regulate B-TFIID activity.

The TATA-box domain is the site of BTAF1's binding to the TATA factor, which is a key regulator of gene expression. The TATA-box domain is composed of a long amino acid sequence that is conserved across different species and is involved in the formation of a DNA-binding motif. This domain is critical for BTAF1's ability to recruit the TATA factor and for the regulation of B-TFIID activity.

The C-terminal region of BTAF1 contains a series of conserved secondary structure elements, including a 尾-sheet and a 纬-helicase. The 尾-sheet is a structural element that is conserved in many proteins and plays a role in the formation of helices. The 纬-helicase is a structural element that is involved in the regulation of protein stability and is often involved in the assembly and disassembly of protein structures.

Potential as a Drug Target

BTAF1 is a protein that has been identified as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This is because of its role in the regulation of B-TFIID-mediated tissue degradation, which is critical for the development and progression of these diseases.

One of the potential mechanisms by which BTAF1 can be targeted is through its role as a negative regulator of B-TFIID activity. B-TFIID is a protein that plays a critical role in the regulation of cellular processes, including cell adhesion, migration, and cytoskeletal organization. It is composed of a protein core and a nucleotide-binding domain that is responsible for the regulation of DNA-binding and gene expression. BTAF1 functions as a negative regulator of B-TFIID activity by binding to the B-TFIID protein and inhibiting its ability to recruit DNA-binding factors.

In addition to its role as a negative regulator of B-TFIID activity, BTAF1 may also be a drug target

Protein Name: B-TFIID TATA-box Binding Protein Associated Factor 1

Functions: Regulates transcription in association with TATA binding protein (TBP). Removes TBP from the TATA box in an ATP-dependent manner

The "BTAF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BTAF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets